This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Owens, D. R Search for Related Content Social Bookmarking                         What's this?

Review: Insulin glulisine — the potential for improved glycaemic control

Diabetes Research Unit, 1st Floor Academic Centre, Llandough Hospital Penlan Road, Penarth, CF64 2XX, UK, owensdr{at}Cardiff.ac.uk

Tight glycaemic control is essential to reduce the risk of developing the micro- and macrovascular complications of diabetes. Plasma levels of glycosylated haemoglobin (HbA _1C) are a marker for long-term glycaemia; controlling these levels within tight limits forms the cornerstone of long-term diabetes management. As a result of evidence from key clinical trials in type 1 and type 2 diabetes, HbA1C targets ranging from < 6.5 to < 7.5% have been set by various authorities. To achieve these targets, insulin regimens need to reflect normal physiological insulin release. Several rapid- and long-acting insulin analogues have been developed to mimic aspects of insulin secretion. Insulin glulisine is a genetically engineered insulin which has a rapid onset and short lived action, allowing it to closely mimic prandial release of insulin. In addition to the structural change in the insulin molecule, the absence of excess zinc and the addition of polysorbate 20 as a surfactant facilitates its disassociation in the subcutaneous tissue and inhibits its aggregation when used in subcutaneous insulin delivery systems due to improved physical stability.

Key Words: insulin glulisine • pharmacokinetics • pharmacodynamics • type 1 diabetes • type 2 diabetes.

References

• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• The Diabetes Control and Complications (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.[Abstract/Free Full Text]
• The DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.[Abstract/Free Full Text]
• Stevens RJ, Coleman RL, Adler AI et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes. UKPDS 66. Diabetes Care 2004;27:201-07.[Abstract/Free Full Text]
• Department of Health. National Service Framework for Diabetes: Delivery Strategy. 2003.
• National Institute for Clinical Excellence. Management of type 2 diabetes: Management of blood glucose (inherited clinical guideline G). 2002.
• National Health Service Confederation and British Medical Association. The new GMS Contract. 2003; http://www.nhsemployers.org/primary/primary-902.cfm.
• Bohannon NJ Optimizing insulin regimens in type 1 diabetes. How to help patients get control of their life. Postgrad Med 2003;113:39-42,45-8,54.[Medline] [Order article via Infotrieve]
• Barnett AH, Capaldi B., Davies-Lyons M. et al. Expert opinion statement on the use of insulin therapy in patients with Type 2 diabetes in primary care. Practical Diabetes International 2003; 20:97-102.[CrossRef]
• Brange J., Owens DR, Kang S. et al. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990;13:923-54.[Abstract]
• Electronic Medicines Compendium. 2006; http://emc.medicines.org.uk
• Becker RH Insulin Glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther 2007 9:109-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Becker RH, Frick AD, Burger F. et al. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005; 113:435-43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Luzio S., Dunseath G., Peter R. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 2006; 49:1163-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003; 26:881-5.[Abstract/Free Full Text]
• DECODE Study Group EDEG. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688-96.[Abstract/Free Full Text]
• Ceriello A., Hanefeld M., Leiter L. et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164:2090-5.[Abstract/Free Full Text]
• Feher MD, Bailey CJ Reclassifying insulins. Br J Diabetes Vasc Dis 2004;4:39-42.[Abstract/Free Full Text]
• Overmann H., Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999;43:137-42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Betz JL Fast-acting human insulin analogs: a promising innovation in diabetes care. Diabetes Educ 1995;21:195-200.[Free Full Text]
• Owens DR, Zinman B., Bolli GB Insulins today and beyond. Lancet 2001;358:739-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Summary of Product Characteristics. emc.medicines.org.uk/
• Becker RH, Frick AD, Burger F. et al. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes 2005;113:292-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Becker RHA, Frick AD, Wessels DH et al. Pharmacodynamics and pharmacokinetics of a new rapidly-acting insulin analog, insulin glulisine. Diabetes 2003;52(suppl 1)pA110(Abstract 471-P).
• Brange J., Langkjoer L. Insulin structure and stability. Pharm Biotechnol 1993;5:315-50.[Medline] [Order article via Infotrieve]
• Hanaire-Broutin H., Schumicki DM, Hoogma Rplm et al. Safety of insulin glulisine compared with insulin aspart administered by continuous subcutaneous insulin infusion (CSII). ADA Conference 2004.
• Frick A., Becker R., Wessels D. et al. Pharmacokinetic and glucodynamic profiles of insulin glulisine following subcutaneous administration at various injection sites. Diabetes 2003;52(suppl 1)A118 (Abstract 511-P).[CrossRef]
• Frick A., Becker R. Predictable and consistent insulin glulisine pharmacokinetics in various populations - an across phase study analysis. Diabetes 2005;54(suppl 11):pA518(Abstract 2154).
• Holmes G., Galitz L., Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005;60:469-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Danne T., Becker RH, Heise T. et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005;28:2100-05.[Abstract/Free Full Text]
• Jaros M., Martinek R., Piechatzek R. et al. Pharmacokinetics of insulin glulisine in non-diabetic renally impaired patients. ADA Conference 2004.
• Nosek L., Becker R., Frick A. et al. Prandial Blood Glucose Control with Pre- and Post-Meal Insulin Glulisine Versus Regular Human Insulin. Diabetes 2004;53(suppl 2):A139(Abstract 588-P).
• Garg S., Rosenstock J., Ways K. Optimized basal-bolus insulin regimens in Type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 2005;11:11-17.[Medline] [Order article via Infotrieve]
• Garg S., Chen Y., Souhami E. Reduction in insulin dose and body weight with pre- and post-meal insulin glulisine (GLU) versus regular human insulin (RHI) in patients with type 1 diabetes. Diabetes 2005;54(suppl 1):A144 (Abstract 581-P).
• Dailey G., Rosenstock J., Moses R. Insulin glulisine provides improved glycaemic control in patients with type 2 diabetes. Diabetes Care 2004;27:2363-8.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 2, 60-66 (2007)
DOI: 10.1177/14746514070070020301


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Owens, D. R Search for Related Content Social Bookmarking                         What's this?